Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | HPGD | P15428 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17747499 | 0.88 | ABCG2 (0.75) | ABCG2MAPTABCC1ALDH1A1HPGD | |
| SCHEMBL17747488 | 0.83 | ABCG2 (0.85) | ABCG2MAPTABCC1ALDH1A1HPGD | |
| SCHEMBL17747435 | 0.82 | ABCG2 (0.83) | ABCG2MAPTABCC1ALDH1A1HPGD | |
| SCHEMBL17747482 | 0.81 | ABCG2 (0.77) | ABCG2MAPTABCC1ALDH1A1HPGD | |
| SCHEMBL17747436 | 0.81 | ABCG2 (1.00) | ABCG2MAPTABCC1ALDH1A1KMT2A | |
| SCHEMBL17747438 | 0.80 | ABCG2 (0.85) | ABCG2MAPTABCC1ALDH1A1HPGD | |
| SCHEMBL17747465 | 0.78 | ABCG2 (0.76) | ABCG2MAPTABCC1ALDH1A1HPGD | |
| SCHEMBL17747472 | 0.78 | ABCG2 (0.75) | ABCG2MAPTABCC1ALDH1A1HPGD | |
| SCHEMBL12562466 | 0.78 | MAPT (0.84) | ABCG2MAPTABCC1ALDH1A1HPGD | |
| SCHEMBL4060486 | 0.78 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152301-A1 | Compounds that Inhibit HIV Particle Formation | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152301-A1 | Compounds that Inhibit HIV Particle Formation | REV1, VPS51, FLOT1 | ABCG2 2375/4885MAPT 1501/4885ABCC1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.